SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTII - Miscellaneous
NTII 0.00010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: John McCarthy1/6/2005 11:40:22 PM
   of 1296
 
2005 - Namenda / Reminyl combo trial for
Moderate to Severe ..

University of Medicine & Dentistry of New Jersey

2. We are seeking patients 50 years and older with generally good health and diagnosed with Alzheimer's disease to participate in a research study evaluating the safety and effectiveness of memantine (Namenda"#8482;) augmented with galantamine (Reminyl"#8482;) in the treatment of patients with moderate to severe Alzheimer's disease. Both these medications have been approved by the FDA. This study will also look at what effect the combination of these two medications has on memory and day to day function. Eligible subjects must be taking Reminyl"#8482; 16 or 24mg per day, be at a stable dose for at least 6 weeks prior to entering the study, and must continue at that dose for the entire study in order to participate. All study medications, which include both Reminyl"#8482; and Namenda"#8482;, will be provided at no cost.

umdnj.edu
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News